Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Total Non-Current Liabilities readings, the most recent being $1.2 billion for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 20.35% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 20.35% increase, with the full-year FY2025 number at $1.2 billion, up 20.35% from a year prior.
  • Total Non-Current Liabilities hit $1.2 billion in Q4 2025 for Neurocrine Biosciences, up from $1.1 billion in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.2 billion in Q4 2025 to a low of $554.3 million in Q2 2022.
  • Median Total Non-Current Liabilities over the past 5 years was $683.6 million (2021), compared with a mean of $777.2 million.
  • Biggest five-year swings in Total Non-Current Liabilities: fell 14.49% in 2022 and later surged 56.57% in 2025.
  • Neurocrine Biosciences' Total Non-Current Liabilities stood at $686.2 million in 2021, then fell by 8.02% to $631.2 million in 2022, then skyrocketed by 44.66% to $913.1 million in 2023, then increased by 5.44% to $962.8 million in 2024, then grew by 20.35% to $1.2 billion in 2025.
  • The last three reported values for Total Non-Current Liabilities were $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $985.4 million (Q2 2025) per Business Quant data.